Next-Generation CAR-T Designs That Could Transform Cancer Treatment
Feb 25, 2026
Cutting-edge CAR-T designs and how they could reshape cancer care are explored. The workflow from cell collection to genetic reprogramming and infusion is outlined. Obstacles in solid tumors like antigen choice and the tumor microenvironment are highlighted. Innovative strategies such as dual-targeting constructs, switchable systems, and ways to reduce toxicities and improve access are discussed.
02:49
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
Clinical Gains And CAR-T Workflow
CAR-T therapy has shown major clinical gains in leukemia, lymphoma, and multiple myeloma, supporting wider adoption of cellular immunotherapy.
The perspective summarizes the CAR-T workflow: leukapheresis, genetic modification and expansion, then infusion, linking process improvements to outcomes.
insights INSIGHT
Why Solid Tumors Resist CAR-T
Solid tumors remain a major barrier for CAR-T due to antigen selection, suppressive tumor microenvironment, and poor T-cell trafficking.
The editorial highlights next-generation strategies like dual-targeting and armored CARs to overcome these solid-tumor limitations.
volunteer_activism ADVICE
Refine CAR Constructs To Reduce Toxicity
Continue refining CAR constructs with dual-targeting, switchable on-off systems, and armored CARs to boost specificity and reduce on-target/off-tumor toxicity.
These design approaches directly target safety and antigen specificity issues raised in the perspective.
Get the Snipd Podcast app to discover more snips from this episode
BUFFALO, NY – February 25, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.”
Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities.
The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols.
“Despite its promise, CAR T-cell therapy faces several critical challenges.”
The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability.
DOI - https://doi.org/10.18632/oncotarget.28836
Correspondence to - Krishnan Hajela - hajelak@gmail.com
Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - cancer, CAR-T therapy, therapeutic approaches
To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh
MEDIA@IMPACTJOURNALS.COM
Oncotarget